UCB SA (OTCMKTS:UCBJF) Stock Now Rated “Moderate Buy” by Sell-Side Brokerages

Shares of UCB SA (OTCMKTS:UCBJF) have received an average rating of “Moderate Buy” from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold recommendation and five have issued a buy recommendation on the company.

Several analysts have recently commented on the stock. Jefferies Financial Group upgraded shares of UCB to a “hold” rating in a research report on Monday, August 3rd. Piper Sandler reaffirmed a “neutral” rating on shares of UCB in a report on Wednesday, July 22nd. Finally, Stephens reaffirmed an “overweight” rating on shares of UCB in a report on Wednesday, October 21st.

UCB Price Performance

UCBJF opened at $321.00 on Friday. UCB has a 1-year low of $219.60 and a 1-year high of $345.39. The company has a 50 day simple moving average of $258.36 and a two-hundred day simple moving average of $286.01. The company has a current ratio of 1.19, a quick ratio of 0.78 and a debt-to-equity ratio of 0.33.

UCB Company Profile

UCB is a Belgium-based biopharmaceutical company focused on discovering, developing and commercializing medicines for people living with severe diseases. Its primary therapeutic areas are neurology and immunology, with research activities spanning conditions such as epilepsy, myasthenia gravis, Parkinson’s disease, psoriasis, psoriatic arthritis, axial spondyloarthritis and other immune-mediated disorders.

The company’s medicines include Bimzelx (bimekizumab), an immunology treatment; Cimzia (certolizumab pegol), used for several inflammatory conditions; and a portfolio of neurological therapies that includes Briviact (brivaracetam), Keppra (levetiracetam), Fintepla (fenfluramine) and Nayzilam (midazolam).